• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai April 26 Cipla saw a 34 per cent dip in its net profit for the fourth quarter or three months ended March 31, 2007, resulting from the export product-mix involving medicines with a lower margin, among other reasons.

The company clocked a net profit after tax of Rs 125.73 crore for the quarter ended March 31, 2007, as compared to Rs 190.77 crore for the quarter ended March 31, 2006. Cipla's Chief Executive Officer, Mr Amar Lulla, told Business Line that higher exports of AIDS drugs in the quarter under review, was one of the reasons. The product-mix has lower margins. However, a year-on-year comparison showed growth on terms better than the company had indicated in the past, he said.

Total income (net of excise) has increased from Rs 919.25 crore for the quarter ended March 31, 2006 to Rs 960.53 crore for the quarter ended March 31, 2007. The company posted a net profit after tax of Rs 660.82 crore for the year ended March 31, 2007 as compared to Rs 607.64 crore for the year ended March 31, 2006. Total income (net of excise) has increased from Rs 3,107.51 crore for the year ended March 31, 2006, to Rs 3,661.27 crore for the year ended March 31, 2007.

More Stories on : Pharmaceuticals | Cipla Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Reliance full year net tops Rs 10,000 crore

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line